Melbourne Clinical Trials

Digestion Study MAD

Inflammatory bowel disease (IBD) is a common chronic inflammatory disease affecting the gastrointestinal tract. It is characterized by abdominal pain, abdominal distension, diarrhoea, vomiting, and weight loss.

13 nights
2 phone follow ups visits

People with Inflammatory bowel disease (IBD) usually require lifelong medical treatment and selective surgery according to the severity of condition. This study is investigating a medication as a potential new treatment for inflammatory bowel disease (IBD).

The study medication is designed to reduce inflammation in the body, and thereby hopefully improve IBD symptoms. At this stage of testing we are looking for healthy participants to test the safety and tolerability of the drug as well as how it is absorbed into the blood stream. At a later stage of testing, the drug will then go on to be tested in patients with IBD to determine whether it will be an effective treatment.

Note there are 3 screening visits with this study.

The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!


Biological Sex Healthy males or females
Age 18 – 55 years old
BMI 18 – 32  kg/m²
Body Weight Males: >50kg and Females: >48 kg
Medications Not taking any (contraceptives permitted)
Medical History Nothing significant
Smoking History Non-smokers or non-heavy smokers (must not smoke more than 5 per days and must abstain 7 days prior to admission and during the study)